Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:small_lymphocytic_lymphoma
gptkb:FDA chronic lymphocytic leukemia follicular lymphoma |
| gptkbp:category |
targeted therapy
|
| gptkbp:discoveredBy |
pharmaceutical companies
|
| gptkbp:example |
gptkb:copanlisib
gptkb:duvelisib gptkb:idelalisib gptkb:umbralisib |
| https://www.w3.org/2000/01/rdf-schema#label |
PI3Kδ inhibitor
|
| gptkbp:mechanismOfAction |
inhibits PI3Kδ enzyme activity
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
infections hepatotoxicity pneumonitis |
| gptkbp:target |
phosphoinositide 3-kinase delta (PI3Kδ)
|
| gptkbp:usedFor |
treatment of autoimmune diseases
treatment of hematological malignancies |
| gptkbp:bfsParent |
gptkb:parsaclisib
|
| gptkbp:bfsLayer |
6
|